liveBook · Manning

Small-molecule compound

As explained in Build AI Drug Discovery Pipelines

A small molecule is a relatively low-molecular-weight chemical compound that can act as a drug or biological-target modulator.

A small-molecule compound is a relatively low-molecular-weight chemical that can act as a drug or modulate a biological target. In RNA-targeted drug discovery, binding can inhibit RNA–protein interactions, alter splicing, or promote RNA degradation. Cancer-related RNA structures provide one therapeutic application. section 6.0

Small-molecule discovery against RNA combines chemical representation with predictive modeling:

  • RNA offers fewer obvious binding pockets than many protein targets and changes among conformations, making binding sites and complexes difficult to characterize. section 6.0
  • Selectivity is difficult because RNA uses four chemically similar nucleotides and contains repeated motifs across the transcriptome. section 6.0
  • A QSAR workflow calculates molecular descriptors across protomer and conformer spaces, selects representative data with Kennard–Stone splitting, reduces dimensions with PCA, and improves models through sequential ensembles. section 6.5

RNA-targeted anticancer discovery

A small molecule designed to bind an RNA structure involved in cancer progression may be evaluated with a QSAR model that relates calculated chemical properties to binding performance. section 6.0 section 6.5

Figure 6.1 The general structure of our QSAR pipeline and major concepts we’ll cover along the way.

Use the pipeline overview to connect molecular representations, descriptor calculation, representative splitting, dimensionality reduction, ensemble learning, and interpretability. section 6.0

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains therapeutic roles, RNA-specific challenges, molecular descriptors, representative splitting, PCA, and sequential ensemble modeling.
Examples
Uses RNA structures involved in cancer progression and compounds evaluated for binding, splicing, RNA degradation, or RNA–protein interaction effects.
What you can do after
Apply QSAR workflows to relate compound properties to RNA-target binding while considering representation, data diversity, and dimensionality.
How it connects
Links small-molecule compounds with RNA, drug discovery, QSAR, molecular descriptors, PCA, and gradient boosting.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.